Abstract:Introduction: Glucose and lipid metabolism disturbances has become the third major disease after cancer and cardio-cerebrovascular diseases. Emerging evidence shows that berberine can effectively intervene glucose and lipid metabolism disturbances, but the underlying mechanisms of this remain unclear. To investigate this issue, we performed metagenomic and metabolomic analysis in a group of normal mice (the NC group), mice with disturbances in glucose and lipid metabolism (the MC group) and mice with disturbances in glucose and lipid metabolism after berberine intervention (the BER group). Result: Firstly, analysis of the clinical indicators revealed that berberine significantly improved the blood glucose and blood lipid of the host. The fasting blood glucose level decreased by approximately 30% in the BER group after 8 weeks and the oral glucose tolerance test showed that the blood glucose level of the BER group was lower than that of the MC group at any time. Besides, berberine significantly reduced body weight, total plasma cholesterol and triglyceride. Secondly, compared to the NC group, we found dramatically decreased microbial richness and diversity in the MC group and BER group. Thirdly, LDA effect size suggested that berberine significantly altered the overall gut microbiota structure and enriched many bacteria, including Akkermansia ( p < 0.01), Eubacterium ( p < 0.01) and Ruminococcus ( p < 0.01). Fourthly, the metabolomic analysis suggested that there were significant differences in the metabolomics signature of each group. For example, isoleucine ( p < 0.01), phenylalanine ( p < 0.05), and arbutin ( p < 0.05) significantly increased in the MC group, and berberine intervention significantly reduced them. The arbutin content in the BER group was even lower than that in the NC group. Fifthly, by combined analysis of metagenomics and metabolomics, we observed that there were significantly negative correlations between the reduced faecal metabolites (e.g., arbutin) in the BER group and the enriched gut microbiota (e.g., Eubacterium and Ruminococcus ) ( p < 0.05) Finally, the correlation analysis between gut microbiota and clinical indices indicated that the bacteria (e.g., Eubacterium ) enriched in the BER group were negatively associated with the above-mentioned clinical indices ( p < 0.05). Conclusion: Overall, our results describe that the changes of gut microbiota and metabolites are associated with berberine improving glucose and lipid metabolism disturbances.

Acute toxicity of berberine and its correlation with the blood concentration in mice

Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats

Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats.

[Comparative study of pharmacokinetics and tissue distribution of 8-cetylberberine and berberine in rats].

Effects of Berberine Hydrochloride on CYP450 Total Content and Expression in BCG-induced Immune Hepatic Injury in Mice and Its Possible Mechanism

A Validated Liquid Chromatographic Method for Berberine Analysis in Tissue and Application

Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats.

Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry

[Effects of berberine on DNFB-induced delayed type hypersensitivity in mice]

Pharmacokinetics of Berberine in Rat Intestinal and Bile Following Intravenous Administration of Coptidis Rhizoma Extract

Pharmacokinetics, Tissue Distribution and Excretion of Demethyleneberberine, a Metabolite of Berberine, in Rats and Mice

Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats

Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine

[Berberine Action Targets and Its Absorption Behavior：how to Use Old Drug for New Mechanisms].

Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism

Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties

Improved up-and-down procedure for acute toxicity measurement with reliable LD50 verified by typical toxic alkaloids and modified Karber method

Pharmacokinetics of Berberine in Healthy Volunteers Studied by LC-MS

Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism

Responses of human gut microbiota abundance and amino acid metabolism in vitro to berberine

Protection Of Gastrointestinal Mucosa From Acute Heavy Alcohol Consumption: The Effect Of Berberine And Its Correlation With Tlr2, 4/Il1 Beta-Tnf Alpha Signaling